KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Johnson & Johnson (JNJ) Cash & Equivalents (2016 - 2025)

Johnson & Johnson's Cash & Equivalents history spans 17 years, with the latest figure at $19.7 billion for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 18.24% year-over-year to $19.7 billion; the TTM value through Dec 2025 reached $19.7 billion, down 18.24%, while the annual FY2025 figure was $19.7 billion, 18.24% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $19.7 billion at Johnson & Johnson, up from $18.2 billion in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $38.5 billion in Q1 2025 and bottomed at $10.5 billion in Q2 2022.
  • The 5-year median for Cash & Equivalents is $18.6 billion (2025), against an average of $18.6 billion.
  • The largest annual shift saw Cash & Equivalents plummeted 35.5% in 2022 before it surged 92.87% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $17.6 billion in 2021, then tumbled by 35.5% to $11.4 billion in 2022, then skyrocketed by 92.51% to $21.9 billion in 2023, then rose by 10.27% to $24.1 billion in 2024, then dropped by 18.24% to $19.7 billion in 2025.
  • Per Business Quant, the three most recent readings for JNJ's Cash & Equivalents are $19.7 billion (Q4 2025), $18.2 billion (Q3 2025), and $18.6 billion (Q2 2025).